T. N. Sys Meryl Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 21-12-2024
- Paid Up Capital ₹ 0.10 M
as on 21-12-2024
- Company Age 18 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.55 Cr
as on 21-12-2024
- Satisfied Charges ₹ 1.80 M
as on 21-12-2024
- Revenue -14.53%
(FY 2021)
- Profit -24.93%
(FY 2021)
- Ebitda -12.40%
(FY 2021)
- Net Worth 23.64%
(FY 2021)
- Total Assets 28.82%
(FY 2021)
About T. N. Sys Meryl Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.55 Cr. The company has closed loans amounting to ₹1.80 M, as per Ministry of Corporate Affairs (MCA) records.
Achala Maharaja and Narendra Chouksey serve as directors at the Company.
- CIN/LLPIN
U24232MP2006PTC019010
- Company No.
019010
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Ujjain, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at T. N. Sys Meryl Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Achala Maharaja  | Director | 12-Oct-2006 | Current |
| Narendra Chouksey | Director | 12-Oct-2006 | Current |
Financial Performance of T. N. Sys Meryl Pharma.
T. N. Sys Meryl Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 14.53% decrease. The company also saw a substantial fall in profitability, with a 24.93% decrease in profit. The company's net worth Soared by an impressive increase of 23.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of T. N. Sys Meryl Pharma?
In 2020, T. N. Sys Meryl Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Meryl Biodiversities & Specialities Private LimitedActive 1 year 4 monthsAchala Maharaja and Narendra Chouksey are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 25 Sep 2024 | ₹7.00 M | Open |
Bank Of India Creation Date: 02 Mar 2021 | ₹0.80 M | Open |
Bank Of India Creation Date: 11 Feb 2020 | ₹4.45 M | Open |
How Many Employees Work at T. N. Sys Meryl Pharma?
T. N. Sys Meryl Pharma has a workforce of 28 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of T. N. Sys Meryl Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped T. N. Sys Meryl Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
